Seeking Alpha

Biogen's (BIIB) BG-12 compound for multiple sclerosis "demonstrated significant and clinically...

Biogen's (BIIB) BG-12 compound for multiple sclerosis "demonstrated significant and clinically meaningful reductions" in relapses and brain lesions in patients with relapsing-remitting MS, data from two Phase III trials show. BG-12 also slowed the progress of the disease. The drug could be on track to become the third oral medicine for MS, as well as the safest and most effective. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|